Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
13
10
2021
accepted:
26
04
2022
revised:
14
04
2022
pubmed:
11
5
2022
medline:
9
8
2022
entrez:
10
5
2022
Statut:
ppublish
Résumé
Mobilized peripheral blood cells (MPBCs) graft and peripheral blood cells apheresis are used for bone marrow transplantation and for treatment of graft versus host disease (GvHD). We demonstrate that a short treatment of MPBCs with Fas ligand (FasL, CD95L) for 2 h using a closed automated cell processing system selectively induces apoptosis of specific donor T cells, B cells and antigen presenting cells, but, critically, not CD34
Identifiants
pubmed: 35538142
doi: 10.1038/s41409-022-01698-3
pii: 10.1038/s41409-022-01698-3
pmc: PMC9088133
doi:
Substances chimiques
Fas Ligand Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250-1259Informations de copyright
© 2022. The Author(s).
Références
Saraceni F, Shem-Tov N, Olivieri A, Nagler A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transpl. 2015;50:886–891. https://doi.org/10.1038/bmt.2014.330 .
doi: 10.1038/bmt.2014.330
Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664–672.
doi: 10.1182/blood.V66.3.664.664
Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806–814. https://doi.org/10.7326/0003-4819-108-6-806 .
doi: 10.7326/0003-4819-108-6-806
pubmed: 3285744
Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175–178. https://doi.org/10.1016/s0140-6736(87)90763-x .
doi: 10.1016/s0140-6736(87)90763-x
pubmed: 2885638
Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–7398. https://doi.org/10.4049/jimmunol.172.12.7393 .
doi: 10.4049/jimmunol.172.12.7393
pubmed: 15187116
Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 2007;110:9–17. https://doi.org/10.1182/blood-2006-12-022038 .
doi: 10.1182/blood-2006-12-022038
pubmed: 17327406
pmcid: 1896131
Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. Br J Haematol. 2016;172:667–684. https://doi.org/10.1111/bjh.13868 .
doi: 10.1111/bjh.13868
pubmed: 26684279
Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A, et al. “Designed” grafts for HLA-haploidentical stem cell transplantation. Blood. 2014;123:967–973. https://doi.org/10.1182/blood-2013-10-531764 .
doi: 10.1182/blood-2013-10-531764
pubmed: 24363403
Levy-Barazany H, Shachnai-Pinkas L, Rodionov G, Saar A, Rosenzwaig M, Gez L, et al. Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance. Bone Marrow Transpl. 2020;55:1305–1316. https://doi.org/10.1038/s41409-020-0941-2 .
doi: 10.1038/s41409-020-0941-2
Cruz FF, Rocco PRM. Cell therapy for acute respiratory distress syndrome patients: the START study. J Thorac Dis. 2019;11:S1329–S1332. https://doi.org/10.21037/jtd.2019.04.22 .
doi: 10.21037/jtd.2019.04.22
pubmed: 31245124
pmcid: 6560575
Guillamat-Prats R, Camprubi-Rimblas M, Bringue J, Tantinya N, Artigas A. Cell therapy for the treatment of sepsis and acute respiratory distress syndrome. Ann Transl Med. 2017;5:446. https://doi.org/10.21037/atm.2017.08.28 .
doi: 10.21037/atm.2017.08.28
pubmed: 29264363
pmcid: 5721220
Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2012;51:1017–1026. https://doi.org/10.1093/rheumatology/ker269 .
doi: 10.1093/rheumatology/ker269
pubmed: 21900368
Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2:640–653. https://doi.org/10.1002/wsbm.86 .
doi: 10.1002/wsbm.86
pubmed: 20890962
pmcid: 2950323
Debili N, Louache F, Vainchenker W. Isolation and culture of megakaryocyte precursors. Methods Mol Biol. 2004;272:293–308. https://doi.org/10.1385/1-59259-782-3:293 .
doi: 10.1385/1-59259-782-3:293
pubmed: 15226552
Psaila B, Barkas N, Iskander D, Roy A, Anderson S, Ashley N, et al. Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Genome Biol. 2016;17:83. https://doi.org/10.1186/s13059-016-0939-7 .
doi: 10.1186/s13059-016-0939-7
pubmed: 27142433
pmcid: 4855892
Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, et al. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 1996;88:1284–1296.
doi: 10.1182/blood.V88.4.1284.bloodjournal8841284
Jeong EM, Yoon JH, Lim J, Shin JW, Cho AY, Heo J, et al. Real-time monitoring of glutathione in living cells reveals that high glutathione levels are required to maintain stem cell function. Stem Cell Rep. 2018;10:600–614. https://doi.org/10.1016/j.stemcr.2017.12.007 .
doi: 10.1016/j.stemcr.2017.12.007
Whitby A, Whitby L, Fletcher M, Reilly JT, Sutherland DR, Keeney M, et al. ISHAGE protocol: are we doing it correctly? Cytom B Clin Cytom. 2012;82:9–17. https://doi.org/10.1002/cyto.b.20612 .
doi: 10.1002/cyto.b.20612
Barnett D, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol. 1999;21:301–308.
doi: 10.1046/j.1365-2257.1999.00253.x
Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr., Crawford JM, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88:3230–3239.
doi: 10.1182/blood.V88.8.3230.bloodjournal8883230
Hilger N, Glaser J, Muller C, Halbich C, Muller A, Schwertassek U, et al. Attenuation of graft-versus-host-disease in NOD scid IL-2Rgamma(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells. Cytom A. 2016;89:803–815. https://doi.org/10.1002/cyto.a.22930 .
doi: 10.1002/cyto.a.22930
Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis. 2006;65:216–221. https://doi.org/10.1136/ard.2005.037143 .
doi: 10.1136/ard.2005.037143
pubmed: 16014673
Erwig LP, Henson PM. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol. 2007;171:2–8. https://doi.org/10.2353/ajpath.2007.070135 .
doi: 10.2353/ajpath.2007.070135
pubmed: 17591947
pmcid: 1941587
Li W. Eat-me signals: keys to molecular phagocyte biology and “appetite” control. J Cell Physiol. 2012;227:1291–1297. https://doi.org/10.1002/jcp.22815 .
doi: 10.1002/jcp.22815
pubmed: 21520079
pmcid: 3242927
Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med. 2010;207:1807–1817. https://doi.org/10.1084/jem.20101157 .
doi: 10.1084/jem.20101157
pubmed: 20805564
pmcid: 2931173
Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME. The consequences of apoptosis in autoimmunity. J Autoimmun. 2008;31:257–262. https://doi.org/10.1016/j.jaut.2008.04.009 .
doi: 10.1016/j.jaut.2008.04.009
pubmed: 18513925
pmcid: 2637382
Lv Z, Bian Z, Shi L, Niu S, Ha B, Tremblay A, et al. Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages. J Immunol. 2015;195:661–671. https://doi.org/10.4049/jimmunol.1401719 .
doi: 10.4049/jimmunol.1401719
pubmed: 26085683
Szondy Z, Sarang Z, Kiss B, Garabuczi E, Koroskenyi K. Anti-inflammatory mechanisms triggered by apoptotic cells during their clearance. Front Immunol. 2017;8:909. https://doi.org/10.3389/fimmu.2017.00909 .
doi: 10.3389/fimmu.2017.00909
pubmed: 28824635
pmcid: 5539239
Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016;23:962–978. https://doi.org/10.1038/cdd.2016.11 .
doi: 10.1038/cdd.2016.11
pubmed: 26915293
pmcid: 4987730
Krahling S, Callahan MK, Williamson P, Schlegel RA. Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages. Cell Death Differ. 1999;6:183–189. https://doi.org/10.1038/sj.cdd.4400473 .
doi: 10.1038/sj.cdd.4400473
pubmed: 10200565
Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21:1605–1619. https://doi.org/10.1089/ars.2014.5941 .
doi: 10.1089/ars.2014.5941
pubmed: 24762207
pmcid: 4175025
Capitano ML, Mohamad SF, Cooper S, Guo B, Huang X, Gunawan AM et al. Mitigating oxygen stress enhances aged mouse hematopoietic stem cell numbers and function. J. Clin. Invest. 2021;131. https://doi.org/10.1172/JCI140177 .
Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K. Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J Biol Chem. 1998;273:8048–8055. https://doi.org/10.1074/jbc.273.14.8048 .
doi: 10.1074/jbc.273.14.8048
pubmed: 9525905
Vogt M, Bauer MK, Ferrari D, Schulze-Osthoff K. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells. FEBS Lett. 1998;429:67–72. https://doi.org/10.1016/s0014-5793(98)00562-6 .
doi: 10.1016/s0014-5793(98)00562-6
pubmed: 9657385
Suzuki M, Aoshiba K, Nagai A. Oxidative stress increases Fas ligand expression in endothelial cells. J Inflamm. 2006;3:11. https://doi.org/10.1186/1476-9255-3-11 .
doi: 10.1186/1476-9255-3-11
Denning TL, Takaishi H, Crowe SE, Boldogh I, Jevnikar A, Ernst PB. Oxidative stress induces the expression of Fas and Fas ligand and apoptosis in murine intestinal epithelial cells. Free Radic Biol Med. 2002;33:1641–1650. https://doi.org/10.1016/s0891-5849(02)01141-3 .
doi: 10.1016/s0891-5849(02)01141-3
pubmed: 12488132
Sarel I, Rodionov G, Ofer A, Rosenzwaig M, Tzadok MS, Rodin A. et al. FasL promotes proliferation and delays differentiation of ASCs. Jpn J Med. 2021;4:474–483.
Zuckerman T, Yehudai-Ofir D, Henig I, Kamar M, Stein J. Safety and preliminary GvHD mitigation in first in human clinical trial of apograft in match related stem cell transplantation (SCT). Blood. 2021;138:2893.
Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 1996;88:2794–2800.
doi: 10.1182/blood.V88.7.2794.bloodjournal8872794
Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702–3709.
pubmed: 10845900
Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1998;21:995–1003. https://doi.org/10.1038/sj.bmt.1701234 .
doi: 10.1038/sj.bmt.1701234
Stem Cell Trialists’ Collaborative G. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–5087. https://doi.org/10.1200/JCO.2005.09.020 .
doi: 10.1200/JCO.2005.09.020
Feng R, Shimazaki C, Inaba T, Takahashi R, Hirai H, Kikuta T, et al. CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 1998;21:1217–1222. https://doi.org/10.1038/sj.bmt.1701273 .
doi: 10.1038/sj.bmt.1701273
Drayer AL, Smit Sibinga CT, Esselink MT, de Wolf JT, Vellenga E. In vitro megakaryocyte expansion in patients with delayed platelet engraftment after autologous stem cell transplantation. Ann Hematol. 2002;81:192–197. https://doi.org/10.1007/s00277-002-0443-x .
doi: 10.1007/s00277-002-0443-x
pubmed: 11976820
Hogge DE, Lambie K, Sutherland HJ, Benny WB, Dalal B, Currie C, et al. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Bone Marrow Transpl. 2000;25:589–598. https://doi.org/10.1038/sj.bmt.1702211 .
doi: 10.1038/sj.bmt.1702211
Takamatsu Y, Harada M, Teshima T, Makino S, Inaba S, Akashi K, et al. Relationship of infused CFU-GM and CFU-Mk mobilized by chemotherapy with or without G-CSF to platelet recovery after autologous blood stem cell transplantation. Exp Hematol. 1995;23:8–13.
pubmed: 7527786
Dercksen MW, Rodenhuis S, Dirkson MK, Schaasberg WP, Baars JW, van der Wall E, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol. 1995;13:1922–1932. https://doi.org/10.1200/JCO.1995.13.8.1922 .
doi: 10.1200/JCO.1995.13.8.1922
pubmed: 7543561
Dercksen MW, Weimar IS, Richel DJ, Breton-Gorius J, Vainchenker W, Slaper-Cortenbach CM, et al. The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Blood. 1995;86:3771–3782.
doi: 10.1182/blood.V86.10.3771.bloodjournal86103771
Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transpl. 2016;51:687–691. https://doi.org/10.1038/bmt.2015.351 .
doi: 10.1038/bmt.2015.351
Trahtemberg U, Mevorach D. Apoptotic cells induced signaling for immune homeostasis in macrophages and dendritic cells. Front Immunol. 2017;8:1356. https://doi.org/10.3389/fimmu.2017.01356 .
doi: 10.3389/fimmu.2017.01356
pubmed: 29118755
pmcid: 5661053
Ward DM. Extracorporeal photopheresis: how, when, and why. J Clin Apher. 2011;26:276–285. https://doi.org/10.1002/jca.20300 .
doi: 10.1002/jca.20300
pubmed: 21898572
Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683–693. https://doi.org/10.1053/j.seminoncol.2012.09.005 .
doi: 10.1053/j.seminoncol.2012.09.005
pubmed: 23206845
Williams DJ, Archer R, Archibald P, Bantounas I, Baptista R, Barker R, et al. Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14-15 September 2015. Regen Med. 2016;11:483–492. https://doi.org/10.2217/rme-2016-0053 .
doi: 10.2217/rme-2016-0053
pubmed: 27404768
pmcid: 5422032
Moutsatsou P, Ochs J, Schmitt RH, Hewitt CJ, Hanga MP. Automation in cell and gene therapy manufacturing: from past to future. Biotechnol Lett. 2019;41:1245–1253. https://doi.org/10.1007/s10529-019-02732-z .
doi: 10.1007/s10529-019-02732-z
pubmed: 31541330
pmcid: 6811377
Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, et al. Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP Working Parties. Front Immunol. 2019;10:1570. https://doi.org/10.3389/fimmu.2019.01570 .
doi: 10.3389/fimmu.2019.01570
pubmed: 31333680
pmcid: 6622152
Oliveira MC, Elias JB, Moraes DA, Simoes BP, Rodrigues M, Ribeiro AAF, et al. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn’s disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther. 2021;43:65–86. https://doi.org/10.1016/j.htct.2020.03.002 .
doi: 10.1016/j.htct.2020.03.002
pubmed: 32418777
Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, van Laar JM, et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017;13:244–256. https://doi.org/10.1038/nrrheum.2017.7 .
doi: 10.1038/nrrheum.2017.7
pubmed: 28228650
Snowden JA, Badoglio M, Alexander T. The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Rev Clin Immunol. 2019;15:981–985. https://doi.org/10.1080/1744666X.2019.1656526 .
doi: 10.1080/1744666X.2019.1656526
pubmed: 31414932
Tobias Alexander RG, John ASnowden. Hematopoietic stem cell transplantation for autoimmune disease. Annu Rev Med. 2021;72:215–218.
doi: 10.1146/annurev-med-070119-115617
Leventhal JR, Mathew JM. Outstanding questions in transplantation: tolerance. Am J Transpl. 2020;20:348–354. https://doi.org/10.1111/ajt.15680 .
doi: 10.1111/ajt.15680
Kawai T, Leventhal J, Wood K, Strober S. Summary of the third international workshop on clinical tolerance. Am J Transpl. 2019;19:324–330. https://doi.org/10.1111/ajt.15086 .
doi: 10.1111/ajt.15086
Strober S. Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. Blood. 2016;127:1539–1543. https://doi.org/10.1182/blood-2015-12-685107 .
doi: 10.1182/blood-2015-12-685107
pubmed: 26796362
pmcid: 4807420
Walker UA, Saketkoo LA, Distler O. Haematopoietic stem cell transplantation in systemic sclerosis. RMD Open. 2018;4:e000533. https://doi.org/10.1136/rmdopen-2017-000533 .
doi: 10.1136/rmdopen-2017-000533
pubmed: 30018796
pmcid: 6045702
Du AX, Osman M, Gniadecki R. Use of extracorporeal photopheresis in scleroderma: a review. Dermatology. 2020;236:105–110. https://doi.org/10.1159/000501591 .
doi: 10.1159/000501591
pubmed: 31362294